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       This  issue  of  the  journal  highlights  some  of  the 
significant advances that have taken place in radiotherapy 
in  recent  years.  The  use  of  ionising  radiation  has  a 
venerable history in cancer treatment. The first recorded 
radiobiology ‘experiment’ occurred in 1898 when Henri 
Becquerel developed a skin reaction to a vial of radium 
kept in his shirt pocket. Skin cancers were successfully 
treated in Stockholm as early as 1899. Throughout the 
20th  century,  rapid  technological  advances  led  to  the 
development of orthovoltage x-ray therapy machines, and 
then in rapid succession, the linear accelerator or ‘linac’ 
and telecobalt apparatus. The development of computer 
technology for treatment planning and delivery late in the 
20th  century  and  more  recently  the  availability  of 
advanced linear accelerators with multileaf collimators, 
capable of independent movement, has transformed the 
capability of radiotherapy to accurately target localised 
cancers.  Radiotherapy  has  been  transformed  from  a 
discipline  that  was  in  danger  of  stagnation  and  was 
becoming marginalised by the rapid advances in systemic 
therapy,  to  a  dynamic  high-technology  therapeutic 
modality at the centre of combined modality therapy for a 
majority  of  the  most  common  cancers.  A  significant 
factor in this resurgence of radiotherapy is the recently 
enhanced ability to precisely deliver therapy to the sites 
of gross disease and to simultaneously reduce irradiation 
of  healthy  normal  tissues.  This  has  the  potential  to 
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minimise  toxicity  while  maximising  the  chance  for 
disease control.  
For  patients  with  potentially  curable  locally  or 
locoregionally  advanced  disease,  conformal  three 
dimensional  treatment  planning  is  now  routine.  The 
availability of complex dosimetric information allows the 
routine  use  of  dose  volume  histogram  analysis  to 
determine  the  dose  delivered  to  precise  volumes  of 
normal tissues. This information is extremely valuable in 
optimising treatment planning to give the safest possible 
dose distribution to normal tissues while adequately and 
uniformly  delivering  dose  to  tumour  volumes.  For  the 
most  complex  planning  situations,  the  routine  use  of 
intensity modulated radiotherapy (IMRT) facilitates the 
delivery of therapy to irregular three dimensional shapes, 
often  with  concave  regions;  an  especially  remarkable 
achievement given that photons travel in straight lines! 
IMRT  has  already  shown  clinical  utility  in  prostate 
cancer,  allowing  very  high  doses  to  be  delivered  with 
acceptable  toxicity  and  with  emerging  evidence  of 
superior disease control [1]. Another outstanding clinical 
example  is  the  use  of  parotid  sparing  IMRT  to  obtain 
tumour control without unacceptable toxicity in head and 
neck  cancers  [2],  especially  carcinomas  of  the 
nasopharynx  [3].  A  chronically  dry  mouth  has 
historically been one of the most distressing toxicities of 
head  and  neck  radiotherapy  [4].  These  complex 
techniques  are  time  consuming,  requiring  laborious 
contouring of tumour and normal tissues on planning CT 
scans  and  they  demand  teamwork  from  radiation 
oncologists,  physicists,  dosimetrists  and  radiation 
therapists.  Further  work  is  required  to  prove  that  the 
additional  complexity  and  expense  is  worthwhile  in  a M. P. Mac Manus. Biomed Imaging Interv J 2006; 2(1):e2  2 
This page number is not  
for citation purposes 
Available online at http://www.biij.org/2006/1/e2/  
range  of  common  clinical  scenarios.  In  many  clinical 
situations,  IMRT  might  actually  represent  an  unduly 
costly treatment option. 
As  our  capacity  to  accurately  deliver  ionising 
radiation in cancer therapy has increased, it has become 
very clear that an accurate assessment of the distribution 
of  tumour  in  3-dimensional  (and  more  recently,  four 
dimensional) space is essential. The basis for conformal 
radiotherapy  planning  has  long  been  the  CT  scan. 
Because of the information on electron density contained 
in  the  CT  dataset,  there  is  no  better  medium  for 
determining  dose  distribution  in  three  dimensions. 
However, at many disease sites, the CT scan has serious 
limitations for delineating the true tumour extent. One of 
the  best  characterised  disease  entities  where  CT  is 
deficient  is  non-small  cell  lung  cancer  (NSCLC). 
Surgical  series  have  shown  that  CT  scanning  is  quite 
poor at determining the true status of mediastinal lymph 
nodes, a crucially important parameter when determining 
the target volumes of the thorax to irradiate in a patient 
with  unresectable  NSCLC.  Another  example  is 
lymphoma where CT scanning is very poor at showing 
disease in a non-enlarged spleen or at other extranodal 
sites such as bowel or salivary gland and cannot detect 
disease in non-enlarged lymph nodes. These deficiencies 
in  CT  imaging  are  a  major  problem  for  planning 
radiotherapy,  when  imaging  must  be  relied  upon  to 
determine  the  gross  tumour  volumes.  Another  crucial 
area where imaging can help is in patient selection for 
aggressive therapy. CT scanning and other conventional 
imaging often fails to detect gross distant metastasis and 
many  patients  have  historically  received  futile  radical 
radiotherapy  when  they  had  incurable  disease  at  the 
outset.  
It is fortuitous that one of the major recent advances 
in the management of cancer has been the rapid progress 
in molecular imaging with positron emission tomography 
(PET)  and  more  recently  with  integrated  PET/CT 
scanners  that  simultaneously  acquire  structural  and 
metabolic  information.  PET  scanning  provides 
complementary  staging  information  to  CT  and  can 
greatly increase the accuracy of disease assessment in a 
range  of  common  cancers.  The  most  successful  PET 
radiopharmaceutical  has  been  18F-fluorodeoxyglucose 
(FDG), a glucose analogue that is selectively taken up by 
and trapped in tumour cells. FDG-PET has proven to be 
of particular value in improving the quality of staging, 
not only in a wide range of epithelial cancers, including 
lung,  head  and  neck,  cervix,  bowel  and  oesophageal 
cancers,  but  also  in  malignant  melanoma,  soft  tissue 
sarcomas and in lymphomas. A meta-analysis has proven 
the  superiority  of  PET  over  CT  in  the  staging  of  the 
mediastinum in NSCLC [5]. The increasing use of PET 
and  especially  PET/CT  for  staging  cancer  and  for 
determining  the  spatial  distribution  of  local  and 
locoregional disease has shown us that, in the past, our 
assessments of cancer patients with conventional imaging 
have often been inadequate. Even if patients selected for 
radical  radiotherapy  really  do  have  potentially  curable 
locoregionally-confined  disease,  without  PET,  many  of 
them  would  have  had  radiotherapy  plans  that  failed to 
treat their disease adequately because of geographic miss. 
Data  from  our  prospective  studies  at  the  Peter 
MacCallum Cancer Centre [6] and other series show that 
PET  can  detect  disease  too  advanced  for  aggressive 
therapy  in  about  one  third  of  candidates  for  radical 
radiotherapy  with  NSCLC.  These  patients  would  be 
unable  to  benefit  from  an  intensive  and  toxic  local 
therapy  and  can  be  spared  from  futile  radical 
chemoradiation because of PET. Simply by using PET to 
exclude  patients  with  a  poor  prognosis,  much  higher 
survival can be observed in a series of patients treated 
with radiotherapy, primarily as a result of better patient 
selection [7]. Treatment planning studies, including those 
from  our  own  centre  and  from  the  University  of 
Washington [8] suggest that, without PET, a quarter or 
more of this patient population would have a geographic 
miss  of  some  gross  tumour.  Therefore,  without  PET 
scanning,  dose  escalation  using  our  new  radiotherapy 
capabilities  would  be  futile  in  many  cases  of  NSCLC. 
Although  lung  cancer  is  the  malignancy  for  which  the 
utility  of  PET  in  radiotherapy  planning  is  best 
established, evidence is accumulating to suggest that it 
may be useful in other cancers such as oesophageal, and 
head and neck cancers [9].  
It  would  be  a  mistake  however,  to  emphasise  the 
technical  advances  in  radiotherapy  and  imaging  in 
isolation.  Radiotherapy  by  itself,  no  matter  how 
technically advanced, can never be a curative therapy in 
its own right for most patients with malignant disease. 
Rapid improvements in our understanding of the biology 
of  cancers  are  bringing  about  a  revolution  in  the 
development of ‘combined modality therapy’ for patients 
with  apparently  locoregionally-confined  malignant 
disease.  Numerous  studies  have  shown  that  platinum-
based chemotherapy improves local disease control and 
often survival in a wide range of tumours treated with 
radiotherapy, including lung [10], head and neck , rectum 
and  cervix.  The  combination  of  accurately  delivered 
radiotherapy with new molecularly-targeted therapies has 
great therapeutic potential. Tirapazemine is a cytotoxic 
agent specific for hypoxic cells that shows great promise 
in combination with radiotherapy [11]. It is now possible 
to attack specific molecular targets in selected cancers, 
such as gastrointestinal stromal tumours (GISTs) using 
imatinib  [12],  a  molecule  that  specifically  targets  the 
surface  tyrosine  kinase  receptor  c-Kit  (CD117),  now 
recognised  as  the  hallmark  immunohistochemical  cell 
marker of GIST. A monoclonal antibody directed at the 
epidermal  growth  factor  receptor  (EGFR),  cetuximab 
[13],  has  been  approved  by  the  U.S.  Food  and  Drugs 
Administration  for  the  treatment  of  patients  with 
colorectal  cancer  who  no  longer  respond  to  standard 
chemotherapy  treatment  with  irinotecan.  Inhibition  of 
EGFR  in  combination  with  radiotherapy  may  have 
therapeutic potential in a range of cancers characterised 
by EGFR overexpression. 
In  conclusion,  these  are  exciting  times  in 
radiotherapy. Advances in radiotherapy technology, and 
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insights  into  tumour  biology  and  new  pharmaceuticals 
are  leading  to  rapid  developments  in  our  approach  to 
patients  with  potentially  curable  cancers.  For  the 
foreseeable future, radiotherapy will remain a critically 
useful tool in our struggle to control malignant disease. 
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